TLDR Vitiligo treatments are improving but relapses are common.
Vitiligo is a chronic autoimmune disorder affecting 0.5-2% of the global population, characterized by the destruction of melanocytes and resulting in depigmented skin patches. Its etiology involves genetic and environmental factors, oxidative stress, and immune response. Recent research explores the role of the skin and gut microbiome and neural factors in its pathogenesis. Treatment remains challenging, with current options like immunosuppressives, phototherapy, and JAK inhibitors providing only short-term benefits, as relapses are common after stopping treatment. New developments are focusing on targeted therapies, such as JAK inhibitors, to improve patient outcomes.
August 2024 in “Bioscience of Microbiota Food and Health” Microbes might play a role in vitiligo.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
532 citations
,
August 2011 in “Journal of the American Academy of Dermatology” Vitiligo is a skin condition causing white spots, more common in women, often starts before age 20, and can affect mental health.
12 citations
,
May 2023 in “EMBO reports” High mTORC1 activity slows hair growth and causes it to lose color.
5 citations
,
June 2012 in “Journal of Investigative Dermatology” A new mouse model for vitiligo helps study immune responses and potential treatments.
2 citations
,
January 2017 in “Journal of Pigmentary Disorders” Vitiligo causes white skin patches and can lead to psychological stress.
January 2017 in “Springer eBooks” The document explains various skin conditions and their treatments.
August 2025 in “Indian Dermatology Online Journal” Combining minoxidil with phototherapy improves vitiligo treatment better than phototherapy alone.